<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915678</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2019-01</org_study_id>
    <secondary_id>2019-000850-78</secondary_id>
    <nct_id>NCT03915678</nct_id>
  </id_info>
  <brief_title>Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors</brief_title>
  <acronym>AGADIR</acronym>
  <official_title>Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seven and Eight Biopharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basket trial concept to independently and simultaneously assess the effects of the&#xD;
      association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      6 independent, multicenter, prospective, single-arm phase II trials, based on 2-stage Simon's&#xD;
      optimal design, will be conducted in parallel to assess the efficacy of atezolimab + BDB001+&#xD;
      radiotherapy, separately, in distinct populations of solid tumors:&#xD;
&#xD;
        -  Population 1: pancreatic cancer&#xD;
&#xD;
        -  Population 2: virus-associated tumors&#xD;
&#xD;
        -  Population 3: anti-PD-1/L1 refractory non-small lung cancer&#xD;
&#xD;
        -  Population 4: soft-tissue sarcoma&#xD;
&#xD;
        -  Population 5: anti-PD-1/L1 refractory bladder cancer&#xD;
&#xD;
        -  Population 6: triple negative breast cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>6 independent single-arm, multicenter, phase II trials, based on 2-stage Simon's optimal design (Simon R, Controlled Clinical Trials 1989):&#xD;
Population 1: pancreatic cancer&#xD;
Population 2: virus-associated tumors&#xD;
Population 3: non-small lung cancer&#xD;
Population 4: soft-tissue sarcoma&#xD;
Population 5: bladder cancer&#xD;
Population 6: triple negative breast cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with pancreatic cancer.</measure>
    <time_frame>Within 6 months of treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with virus associated tumors.</measure>
    <time_frame>Within 6 months of treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with non-small cell lung cancer.</measure>
    <time_frame>Within 6 months of treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with soft-tissue sarcoma.</measure>
    <time_frame>6 months of treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of 6-month progression-free rat (PFR) and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed at 6 months following treatment onset and more than 24 weeks, based on RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with bladder cancer.</measure>
    <time_frame>Within 6 months of treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with triple negative breast cancer.</measure>
    <time_frame>Within 6 months of treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of disease control rate within 24 weeks of treatment onset and is defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) observed within 24 weeks of treatment onset (while treated with the investigational product), based on RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-free rate (PFR) in patients with pancreatic cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-free rate (PFR) in patients with virus-associated tumor.</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-free rate (PFR) in patients with non-small cell lung cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-free rate (PFR) in patients with bladder cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-free rate (PFR) in patients with triple negative breast cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free rate is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month objective response rate (ORR) independently for each population.</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed at 6 months, based on RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) within 24 weeks of treatment onset, independently for each population.</measure>
    <time_frame>Within 6 months</time_frame>
    <description>Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed within 24 wekks after treatment onset, based on RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response, independently for each population.</measure>
    <time_frame>Throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Best overall response is defined as the best response across all time points (RECIST 1.1). The best overall response is determined once all the data for the patient is known (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression-free survival, independently for each population.</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival, independently for each population.</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival, independently for each population.</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival, independently for each population.</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile, independently for each population: Common Terminology Criteria for Adverse Events version 5</measure>
    <time_frame>Throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Toxicity graded using the Common Terminology Criteria for Adverse Events version 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor immune cells levels</measure>
    <time_frame>before treatment onset and cycle 3 day 1 (each cycle is 21 days)</time_frame>
    <description>Levels of immune cells in tumor will be measured by immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cytokines levels</measure>
    <time_frame>baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)</time_frame>
    <description>Levels of cytokines in blood will be measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lymphocytes levels</measure>
    <time_frame>baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)</time_frame>
    <description>Levels of lymphocytes in blood will be measured by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood kynurenine levels</measure>
    <time_frame>baseline, cycle 1 day 1, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)</time_frame>
    <description>Levels of kynurenine in blood will be measured by ELISA.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">247</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Virus-associated Tumors</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Bladder Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Population 1: Pancreatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population 2: Virus-associated tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population 3: anti-PD-1/L1 refractory non-small lung cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population 4: Soft-tissue sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population 5: anti-PD-1/L1 refractory bladder cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population 6: Triple negative breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association atezolizumab + BDB001 + RT</intervention_name>
    <description>A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).&#xD;
BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.&#xD;
Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.</description>
    <arm_group_label>Population 1: Pancreatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association atezolizumab + BDB001+ RT</intervention_name>
    <description>A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).&#xD;
BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.&#xD;
Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.</description>
    <arm_group_label>Population 2: Virus-associated tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association atezolizumab + BDB001+ RT</intervention_name>
    <description>A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).&#xD;
BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.&#xD;
Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.</description>
    <arm_group_label>Population 3: anti-PD-1/L1 refractory non-small lung cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association atezolizumab + BDB001 + RT</intervention_name>
    <description>A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).&#xD;
BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.&#xD;
Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.</description>
    <arm_group_label>Population 4: Soft-tissue sarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association atezolizumab + BDB001 + RT</intervention_name>
    <description>A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).&#xD;
BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.&#xD;
Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.</description>
    <arm_group_label>Population 5: anti-PD-1/L1 refractory bladder cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association atezolizumab + BDB001 + RT</intervention_name>
    <description>A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).&#xD;
BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.&#xD;
Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.</description>
    <arm_group_label>Population 6: Triple negative breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. histologically confirmed pancreatic cancer, virus-associated tumors [including&#xD;
             papillomaviruses-related cancers (cervical, head and neck, and nasal), Epstein-Barr&#xD;
             virus (nasopharyngeal carcinoma) and Kaposi's sarcoma-associated herpes virus),&#xD;
             non-small cell lung cancer, soft-tissue sarcomas, bladder cancer, triple negative&#xD;
             breast cancer. For population 4, diagnosis must be confirmed by the RRePS Network as&#xD;
             recommended by the French NCI,&#xD;
&#xD;
          2. Metastatic disease,&#xD;
&#xD;
          3. Age ≥ 18 years,&#xD;
&#xD;
          4. ECOG ≤ 1,&#xD;
&#xD;
          5. At least two lesions: one lesion that can be treated by radiotherapy and one site of&#xD;
             disease that must be uni-dimensionally ≥ 10 mm considered as measurable according to&#xD;
             RECIST v1.1. This lesion will not be treated by radiotherapy, however, note that&#xD;
             lesion(s) that will be treated by radiotherapy will also be considered as measurable.&#xD;
             Note that the largest size of the metastases to be irradiated will be 3cm,&#xD;
&#xD;
          6. Life expectancy &gt; 6 months,&#xD;
&#xD;
          7. At least one tumor site that can be biopsied for research purpose. Tumor lesion in&#xD;
             close proximity to vascular structures such as large vessels, aneurysm or pulmonary&#xD;
             arteriovenous malformation will not be considered for biopsy,&#xD;
&#xD;
          8. Availability of archived paraffin-embedded tumor tissue for research purpose,&#xD;
&#xD;
          9. Participant must have advanced disease and must not be a candidate for other approved&#xD;
             therapeutic regimen known to provide significant clinical benefit based on&#xD;
             investigator judgement,&#xD;
&#xD;
         10. Participants who received prior anti-PD-1/L1 therapy must fulfill the following&#xD;
             requirements - population 3 and population 5 only&#xD;
&#xD;
               -  Have achieved a complete response, partial response or stable disease and&#xD;
                  subsequently had disease progression while still on anti-PD-1/L1 therapy&#xD;
&#xD;
               -  Have received at least two doses of an approved anti-PD-1/L1 therapy (by any&#xD;
                  regulatory authority)&#xD;
&#xD;
               -  Have demonstrated disease progression as defined by RECIST v1.1 within 18 weeks&#xD;
                  from the last dose of the anti- PD-1/L1 therapy.&#xD;
&#xD;
         11. Adequate hematological, renal, metabolic and hepatic functions&#xD;
&#xD;
         12. No prior or concurrent malignant disease needing an active treatment,&#xD;
&#xD;
         13. At least three weeks since last chemotherapy, immunotherapy or any other&#xD;
             pharmacological treatment and/or radiotherapy,&#xD;
&#xD;
         14. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment,&#xD;
             excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2,&#xD;
&#xD;
         15. Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to inclusion.&#xD;
&#xD;
         16. Both women and men must agree to use an effective method of contraception throughout&#xD;
             the treatment period and for five months after discontinuation of treatment.&#xD;
&#xD;
         17. Voluntary signed and dated written informed consents prior to any specific study&#xD;
             procedure,&#xD;
&#xD;
         18. Participants with a social security in compliance with the French law.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Previous treatment with a TLR agonist&#xD;
&#xD;
          2. Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal&#xD;
             metastases,&#xD;
&#xD;
          3. Women who are pregnant or breast feeding,&#xD;
&#xD;
          4. Participation in a study involving a medical or therapeutic intervention in the last&#xD;
             30 days,&#xD;
&#xD;
          5. Known hypersensitivity to CHO cell products or to any involved study drug or of its&#xD;
             formulation components,&#xD;
&#xD;
          6. History of severe allergic anaphylactic reactions to chimeric, human or humanized&#xD;
             antibodies, or fusion proteins,&#xD;
&#xD;
          7. Treatment with systemic immunosuppressive medications including, but not limited to,&#xD;
             cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents within&#xD;
             2 weeks prior to inclusion.&#xD;
&#xD;
          8. Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             before inclusion,&#xD;
&#xD;
          9. Any of the following cardiac criteria: congestive heart failure ≥ New York Heart&#xD;
             Association (NYHA) class 2, unstable angina, new-onset angina, myocardial infarction&#xD;
             less than 6 months before inclusion, uncontrolled cardiac arrhythmias, known left&#xD;
             ventricular ejection fraction (LVEF) &lt;50%&#xD;
&#xD;
         10. Individuals deprived of liberty or placed under legal guardianship,&#xD;
&#xD;
         11. Prior organ transplantation, including allogeneic stem cell transplantation,&#xD;
&#xD;
         12. Known clinically significant liver disease, including active viral, alcoholic, or&#xD;
             other hepatitis, cirrhosis, fatty liver and inherited liver disease,&#xD;
&#xD;
         13. History of intra-abdominal inflammatory process within the last 12 months such as, but&#xD;
             not limited to, diverticulitis, peptic ulcer disease or colitis.&#xD;
&#xD;
         14. History of autoimmune disease including, but not limited to systemic lupus&#xD;
             erythematosus (SLE), Sjögren's syndrome, glomerulonephritis, multiple sclerosis,&#xD;
             rheumatoid arthritis, vasculitis, systemic immune activation, inflammatory bowel&#xD;
             disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's&#xD;
             granulomatosis, Guillain-Barré syndrome, Bell's palsy.&#xD;
&#xD;
         15. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest CT scan.&#xD;
&#xD;
         16. Poorly controlled Type II diabetes mellitus defined as a screening fasting plasma&#xD;
             glucose ≥160 mg/dL (or 8.8 mmol/L).&#xD;
&#xD;
         17. Severe infections within 2 weeks prior to inclusion, including but not limited to&#xD;
             SARS-Cov-2 infection, hospitalization for complications of infection, bacteremia, or&#xD;
             severe pneumonia.&#xD;
&#xD;
         18. Received therapeutic oral or IV antibiotics within 2 weeks prior to inclusion.&#xD;
&#xD;
         19. Participant has spinal cord compression not definitively treated with surgery and/or&#xD;
             radiation or previously diagnosed and treated spinal cord compression without evidence&#xD;
             that disease is clinically stable at least 14 days prior to inclusion.&#xD;
&#xD;
         20. Administration of a live, attenuated vaccine within 4 weeks before the start of study&#xD;
             medication .&#xD;
&#xD;
         21. Has known active hepatitis B or hepatitis C,known history of Human Immunodeficiency or&#xD;
             known acquired immunodeficiency syndrome, known history of tuberculosis&#xD;
&#xD;
         22. Patients with current retinal disorder confirmed by retinal examination (external&#xD;
             ocular examination, routine slit lamp biomicroscopy of anterior ocular structures and&#xD;
             evaluation of the anterior and posterior chamber,&#xD;
&#xD;
         23. Patients who wear contact lenses unable to replace them with glasses.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <phone>+33 5.56.33.33.33</phone>
    <email>a.italiano@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, MD, PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, MD, PhD</last_name>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe METGES, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe METGES, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David PASQUIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>David PASQUIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clélia COUTZAC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clélia COUTZAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe ROCHIGNEUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe ROCHIGNEUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego TOSI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diego TOSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Paule SABLIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Paule SABLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine HIRET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandrine HIRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopôle</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Alberto GOMEZ-ROCA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Alberto GOMEZ-ROCA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane CHAMPIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane CHAMPIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Oncology</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

